Fierce Pharma June 20, 2024
Hikma, a London-based generics maker, has agreed to buy parts of Xellia’s assets in the U.S., including the Danish drugmaker’s manufacturing facility in Cleveland.
Hikma will pay $135 million in cash with an additional $50 million going to Xellia based on contingencies, the company said in a June 17 press release. The deal is subject to approval from the U.S. Federal Trade Commission.
Under terms of the transaction, Hikma gets the Cleveland facility that features end-to-end capabilities to develop, manufacture, pack and distribute lyophilized vials and aseptically filled ready-to-use IV bag products.
The generic drugmaker revealed plans to invest an undisclosed amount into the facility to boost productivity by adding automation, equipment and updated processes. Hikma aims to complete the...
Today's Sponsors
Today's Sponsor